Enveric Biosciences to Participate in Upcoming Investor Conferences in September 2021

Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on mental health and oncology treatments, announced participation in two investor conferences. CEO Dr. Joseph Tucker will take part in the Maxim's Advances in Mental Health Virtual Conference on September 22 at 10:00 a.m. ET, discussing 'Next Gen Psychedelics: Novel Chemical Entities'. He will also present at the Benzinga's Healthcare Small Cap Virtual Conference on September 30 at 3:40 p.m. ET. Enveric aims to address mental health issues using psychedelic-derived molecules and synthetic cannabinoids.

NAPLES, Fla., Sept. 20, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform for the mind and body using psychedelics and cannabinoids, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in two upcoming investor conferences:

Maxim's Advances in Mental Health Virtual Conference
Wednesday, September 22^nd at 10:00 a.m. ET
Panel titled: Next Gen Psychedelics: Novel Chemical Entities
To attend, register here

Benzinga's Healthcare Small Cap Virtual Conference
Thursday, September 30^th at 3:40 p.m. ET
To attend, register here

For more information about the conferences, or to schedule a one-on-one meeting with Enveric's management, please contact your appropriate representative directly, or send an email to Maxim at jthompson@maximgrp.com, Benzinga at VIPevents@benzinga.com, or KCSA Strategic Communications at EnvericBio@kcsa.com.

About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric's robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For more information, please visit www.enveric.com.

Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
valter@kcsa.com / asoss@kcsa.com 

Media Contacts
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
212.896.1241 / 212.896.1204
ckasunich@kcsa.com / rcona@kcsa.com 

View original content:https://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-upcoming-investor-conferences-in-september-2021-301380168.html

SOURCE Enveric Biosciences

FAQ

What events will Enveric Biosciences participate in September 2021?

Enveric Biosciences will participate in Maxim's Advances in Mental Health Virtual Conference on September 22 and Benzinga's Healthcare Small Cap Virtual Conference on September 30.

Who is presenting for Enveric at the upcoming investor conferences?

CEO Dr. Joseph Tucker will present for Enveric Biosciences at the upcoming investor conferences.

What topics will be discussed at the Maxim's Advances in Mental Health Virtual Conference?

The panel at Maxim's conference will focus on 'Next Gen Psychedelics: Novel Chemical Entities'.

What is the focus of Enveric Biosciences' clinical discovery platform?

Enveric Biosciences focuses on mental health and oncology treatments using psychedelics and cannabinoids.

How can I register for the investor conferences featuring Enveric Biosciences?

Registration for Maxim's conference can be done through their website, and for Benzinga's conference, registration is also available online.